 multiple myeloma.webp)
TALVEY™ (talquetamab-tgvs) is a newly approved drug indicated for the treatment of highly refractory multiple myeloma [Ref].
It is indicated for the treatment of multiple myeloma in adult patients who have relapsed or those who are refractory to at least 4 first line of treatment, including:
- Proteasome Inhibitor (Bortezomib)
- An Immunomodulatory agent (thalidomide, lenalidomide, and pomalidomide), and
- Anti-CD 38 antibody (Daratumumab, Isatuximab, and Elotuzumab)
Talquetamab targets 2 receptors: CD-3 positive T cells and GPRC5D (G protein-coupled receptor, family C, group 5, member D).
GPRC5D is specifically expressed in the plasma cells of patients with multiple myeloma.
In a clinical trial, the response rate documented with Talvey at different doses was significant compared to other FDA-approved medications.
The table below summarizes the response rate of Talvey in comparison with other drugs [Ref]:
Treatment |
Response Rate (%) |
|
Talquetamab 405-μg dose |
65% |
|
Talquetamab 800-μg dose |
70% |
|
Selinexor + Dexamethasone |
25% |
|
Belantamab Mafodotin |
31% |
|
Idecabtagene Vicleucel |
67% |
|
Ciltacabtagene Autoleuce |
83% |
Contraindications, Precautions, and Side Effects of Talvey (Talquetamab):
Like most potent biological medicines and drugs targeting specific immune cells, Talvey (Talquetamab) is associated with significant side effects including:
- Cytokine Release Syndrome (CRS). Symptoms of CRS include:
-
Fever and chills
-
Fatigue
-
Headache
-
Nausea and Vomiting
-
Muscle and joint pain
-
Tachycardia
-
Hypotension
-
Difficulty breathing
-
Swelling
-
Skin rash
-
Confusion or delirium
-
Seizures
-
Organ dysfunction (such as liver or kidney impairment)
-
Capillary leak syndrome (fluid leakage from blood vessels)
-
- Neurotoxicity including ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome)
- Oral toxicity manifests as altered taste, dry mouth, dysphagia, difficulty swallowing, and stomatitis.
- Weight loss
- Infections including serious infections such as fungal and serious bacterial and viral infections (COVID pneumonia)
- Bone marrow suppression manifesting as low platelet counts, anemia, and neutropenia.
- Skin toxicity may manifest as a rash or may be severe and manifest as Steven-Johnson syndrome.
- Liver toxicity manifesting as raised liver functions and jaundice.
 for extensive stage small cell lung cancer.webp)